Artificial intelligence (AI) is being employed in the UK to accelerate and enhance the diagnosis of dementia. The initiative, launched by the Aneurin Bevan University Health Board in southeast Wales, is the first of its kind in the country. Eventually, the study aims to include 1,000 patients across the UK, providing early detection and intervention for those affected.
Personal Struggles Highlight Urgent Need
For patients like Kathryn White, a 74-year-old retired postmistress from Pontllanffraith, Caerphilly, obtaining a clear diagnosis can take years. Kathryn underwent numerous tests over two-and-a-half years before being diagnosed with Alzheimer’s disease. Her experience underscores the urgent need for improved diagnostic methods.
Kathryn first noticed cognitive difficulties while driving familiar routes, becoming confused and unable to navigate. “I couldn’t remember how to get to Cardiff,” she recalled, highlighting the everyday challenges dementia imposes. These incidents eventually prompted a visit to her local GP.
Combining Biomarkers and AI
The study utilizes advanced blood tests to detect biomarkers, tiny proteins in the blood that indicate early Alzheimer’s changes. AI then integrates these results to create a clearer diagnostic picture. Unlike traditional methods, which often require invasive procedures such as lumbar punctures, blood biomarker testing is less invasive and can potentially provide faster results.
Michael White, Kathryn’s husband, welcomed the study. “Everything came back inconclusive over two-and-a-half years,” he said. Eventually, a lumbar puncture confirmed the diagnosis, a process the new AI-assisted approach may streamline in the future.
Potential Benefits for Patients
The goal of the study is to reduce waiting times and enable earlier intervention for dementia patients. Dr. Chineze Ivenso, lead for dementia at Health and Care Research Wales (HCRW), explained: “Millions of people worldwide will have dementia in the coming years, with Alzheimer’s being the most common form. Early detection allows treatment and support at an earlier stage.”
Incorporating AI alongside conventional cognitive tests and imaging could improve diagnostic accuracy. Currently, evidence suggests that around 70% of dementia diagnoses are accurate, leaving a significant 30% potentially misdiagnosed.
How the Diagnostic Process Works
Traditional dementia assessment relies on patient history, symptom evaluation, brain imaging, and cognitive tests that measure memory and problem-solving skills. The new approach supplements these evaluations with blood biomarker detection, allowing for the identification of early Alzheimer’s indicators before symptoms become severe.
“These biomarkers are incredibly promising,” Dr. Ivenso noted. “When combined with AI, they could significantly improve diagnostic reliability.”
About Dementia and Alzheimer’s
Dementia describes a set of symptoms caused by conditions that damage brain cells and their connections. Alzheimer’s disease, the most common form, involves abnormal protein accumulation in and around brain cells. The risk of developing Alzheimer’s doubles every five years after the age of 65, though around 5% of patients are under 65.
Nearly one million people in the UK are living with dementia, and rates are expected to rise sharply over the next 15 years due to an ageing population. While there is no cure, current treatments can manage symptoms, and new therapies are in development. The economic burden of dementia in the UK is estimated at £42bn annually as of 2024, projected to reach £90bn by 2040.
Study Leadership and Support
The study is led by Imperial College London and sponsored by the AI neuroscience company Prima Mente. In Wales, the trial is supported by HCRW. Dr. Nicola Williams, director of research at HCRW, emphasized Wales’ strong track record in medical research, noting that approximately 250,000 participants have taken part in trials over the past decade.
Conclusion
By integrating AI with biomarker detection and traditional cognitive tests, researchers hope to transform dementia care. Faster, more accurate diagnoses mean patients can receive treatment and support sooner, potentially slowing disease progression and improving quality of life.
Related topics
